Thus, to assess the immunomodulatory effect of JQ1, we treated p53 wild-type NB cell lines with JQ1 and, at pre-apoptotic dose, we evaluated the expression levels of activating ligands and NB cell susceptibility to NK cell-mediated recognition and lysis in response to JQ1-mediated MYCN downregulation. The gene discussed is TP53; the disease is neuroblastoma.